Mustang Bio (MBIO) Change in Account Payables (2016 - 2026)
Mustang Bio (MBIO) posted quarterly Change in Account Payables of $18000.0 for Q1 2026, down 87.67% year-over-year from $146000.0 in Q1 2025, and up 169.23% quarter-over-quarter from -$26000.0 in Q4 2025.
Mustang Bio (MBIO) Change in Account Payables (2016 - 2026) Analysis & Trends
Mustang Bio (MBIO) has reported Change in Account Payables for 11 consecutive years, with $18000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables fell 87.67% year-over-year to $18000.0; the TTM figure through Mar 2026 stood at -$292000.0 (down 130.45% YoY), while the FY2025 annual figure was -$164000.0, down 108.95% from the prior year.
- Change in Account Payables improved to $18000.0 in Q1 2026 per MBIO's latest filing, from -$26000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $1.0 million in Q1 2024 and bottomed at -$363000.0 in Q2 2022.
- Historically, Change in Account Payables has averaged $105705.9 across 5 years, with a median of $88000.0 in 2022.
- Annual changes were most pronounced in 2022 — Change in Account Payables sank 729.79% — and 2024, when it soared 718.18%.
- Mustang Bio's Change in Account Payables stood at $614000.0 in 2022, then sank by 128.01% to -$172000.0 in 2023, then surged by 176.74% to $132000.0 in 2024, then plunged by 119.7% to -$26000.0 in 2025, then jumped by 169.23% to $18000.0 in 2026.
- Business Quant data shows MBIO's Change in Account Payables at $18000.0 in Q1 2026, -$26000.0 in Q4 2025, and $25000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Mustang Bio | 3.90 Mn | 3.90 Mn | - | 19,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19,000.00 |
| Jun 30, 2026 | 19,000.00 |
| Mar 31, 2026 | 18,000.00 |
| Mar 31, 2026 | 18,000.00 |
| Dec 31, 2025 | -26,000.00 |
| Dec 31, 2025 | -26,000.00 |
| Sep 30, 2025 | 25,000.00 |
| Sep 30, 2025 | 25,000.00 |
| Jun 30, 2025 | -309,000.00 |
| Jun 30, 2025 | -309,000.00 |
| Mar 31, 2025 | 146,000.00 |
| Mar 31, 2025 | 146,000.00 |
| Dec 31, 2024 | 132,000.00 |
| Dec 31, 2024 | 132,000.00 |
| Sep 30, 2024 | 231,000.00 |
| Sep 30, 2024 | 231,000.00 |
| Jun 30, 2024 | 450,000.00 |
| Jun 30, 2024 | 450,000.00 |
| Mar 31, 2024 | 1.02 Mn |
| Mar 31, 2024 | 1.02 Mn |